Let's say that a company in Greece develops and wants you to market its drug (which falls under the products that undergo a central procedure): A. If the company wants the drug to be marketed only in another European country, to which body should it submit the Clinical Trial Application (CTA) and to which the Marketing Authorization Application (MAA)? B. If the company wants the drug to be marketed both in Greece and in all European countries, to which body should it submit the Clinical Trial Application (CTA) and to whom the Marketing Authorization Application (MAA)?